Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2928 plus Azacitidine in Hematological Malignancies
NCT06008405Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Sep 2023
- Primary completion
- May 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of tqb2928 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Incidence of Adverse Events up to 2 years, Incidence of Serious Adverse Events up to 2 years and 1 more. Status: unknown.
02
Drugs
tqb2928
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06008405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06008405.